Please ensure Javascript is enabled for purposes of website accessibility

Here's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today

By Cory Renauer – May 10, 2017 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Array Biopharma's financial results get the back seat today, while clinical-trial results ride shotgun.

What happened

Shares of Array Biopharma Inc. (ARRY), a biotech with several new drug candidates in late development stages, is surging after the release of clinical trial results along with an earnings report. Despite slight misses on the top and bottom lines, at 11 a.m. EDT during Wednesday's session, the stock was 23.15% higher than at Tuesday's close.

So what

It's Columbus Day at Array Biopharma after the company announced successful results from part 2 of the COLUMBUS study. In part 1, Array's experimental combination of 45mg binimetinib plus 450mg encorafenib wiped the floor with a standard treatment for a genetically defined group of advanced melanoma patients.

A person in a business suit looks at a cloud shaped like an upward-sloping arrow.

Image source: Getty Images.

The experimental combination, named COMBO450, outperformed a standard treatment for these patients, but there were some concerns about binimetinib's role. In COLUMBUS part 1, the survival benefit COMBO450 provided was longer than encorafenib alone, but not quite enough to be considered statistically significant.

Investors are cheering the results of COLUMBUS part 2 because it suggests binimetinib is indeed pulling its own weight for the combo. Yesterday's release showed a combination of 45mg binimetinib plus 300mg encorafenib (COMBO300) significantly outperformed encorafenib on its own.

Now what

While COLUMBUS part 2's success might not seem like a huge deal, it keeps Array Biopharma on track to file a new drug application for the combination as intended. Based on the strength of data from both trials, the company expects to submit an application to the U.S. Food and Drug Administration in June or July, and the company's European marketing partner is on track to submit an application to EU regulators this summer as well. Of course, an approval would send the stock soaring.

Based on the results, I wouldn't be surprised if Array's combo begins competing with the therapy it bested in the clinic, Zelboraf from Roche. Last year the drug generated about $211 million in sales for the Swiss drugmaker, and it's not hard to imagine Array's combo outperforming Zelboraf in terms of peak sales as well.

A few hundred million might be a drop in the bucket for Roche, but it would be a huge boost for Array. At recent prices, the biotech sports a $1.45 billion market cap but doesn't have any products to sell just yet. What it does have is a late-stage pipeline with seven candidates (including encorafenib and binimetinib) in trials intended to support new drug applications.

Array finished March with about $207 million in cash and securities on its balance sheet. Development costs tend to rise as candidates approach the finish line, and some product revenue would add a nice extension to the company's cash runway.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.